W. Clay Gustafson, M.D.

Pediatric cancer specialist

Dr. W. Clay Gustafson is a pediatric cancer specialist in the Cancer and Blood Disease Program at UCSF Benioff Children's Hospital. He is a physician scientist with both a clinical and laboratory interest in developing novel therapeutics for pediatric solid tumors, particularly neuroblastoma. Clinically, he focuses largely on Phase I and II clinical trials for neuroblastoma. He holds several grants focused on unique treatment approaches to cancer.

Gustafson earned an undergraduate degree in biochemistry and English literature at Rice University in Houston, Texas. He earned his medical degree and PhD from the University of Texas Medical Branch. He completed a residency in pediatrics at the University of Texas Southwestern Medical Center in Dallas, Texas and a fellowship in pediatric hematology and oncology at UCSF. He is an assistant professor of pediatrics.

More about W. Clay Gustafson

Education

University of Texas School of Medicine at Galveston 2005

Residencies

University of Texas Southwestern Medical Center, 2008

Fellowships

UCSF Medical Center, 2011

Selected Research and Publications

  1. Hackett CS, Quigley DA, Wong RA, Chen J, Cheng C, Song YK, Wei JS, Pawlikowska L, Bao Y, Goldenberg DD, Nguyen K, Gustafson WC, Rallapalli SK, Cho YJ, Cook JM, Kozlov S, Mao JH, Van Dyke T, Kwok PY, Khan J, Balmain A, Fan Q, Weiss WA. Expression Quantitative Trait Loci and Receptor Pharmacology Implicate Arg1 and the GABA-A Receptor as Therapeutic Targets in Neuroblastoma. Cell Rep. 2014 Nov 6; 9(3):1034-46.
  2. Gustafson WC, Meyerowitz JG, Nekritz EA, Chen J, Benes C, Charron E, Simonds EF, Seeger R, Matthay KK, Hertz NT, Eilers M, Shokat KM, Weiss WA. Drugging MYCN through an Allosteric Transition in Aurora Kinase A. Cancer Cell. 2014 Sep 8; 26(3):414-27.
  3. Yu D, Gustafson WC, Han C, Lafaye C, Noirclerc-Savoye M, Ge WP, Thayer DA, Huang H, Kornberg TB, Royant A, Jan LY, Jan YN, Weiss WA, Shu X. An improved monomeric infrared fluorescent protein for neuronal and tumour brain imaging. Nat Commun. 2014; 5:3626.
  4. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, Asthana S, Jalbert LE, Nelson SJ, Bollen AW, Gustafson WC, Charron E, Weiss WA, Smirnov IV, Song JS, Olshen AB, Cha S, Zhao Y, Moore RA, Mungall AJ, Jones SJ, Hirst M, Marra MA, Saito N, Aburatani H, Mukasa A, Berger MS, Chang SM, Taylor BS, Costello JF. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014 Jan 10; 343(6167):189-93.
  5. Fan QW, Cheng CK, Gustafson WC, Charron E, Zipper P, Wong RA, Chen J, Lau J, Knobbe-Thomsen C, Weller M, Jura N, Reifenberger G, Shokat KM, Weiss WA. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell. 2013 Oct 14; 24(4):438-49.
  6. Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, Garnett MJ, McDermott U, Benes CH, Kung AL, Weiss WA, Bradner JE, Stegmaier K. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013 Mar; 3(3):308-23.
  7. Seo Y, Gustafson WC, Dannoon SF, Nekritz EA, Lee CL, Murphy ST, VanBrocklin HF, Hernandez-Pampaloni M, Haas-Kogan DA, Weiss WA, Matthay KK. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model. Mol Imaging Biol. 2012 Dec; 14(6):735-42.
  8. Cheng CK, Gustafson WC, Charron E, Houseman BT, Zunder E, Goga A, Gray NS, Pollok B, Oakes SA, James CD, Shokat KM, Weiss WA, Fan QW. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma. Proc Natl Acad Sci U S A. 2012 Jul 31; 109(31):12722-7.
  9. Chanthery YH, Gustafson WC, Itsara M, Persson A, Hackett CS, Grimmer M, Charron E, Yakovenko S, Kim G, Matthay KK, Weiss WA. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Sci Transl Med. 2012 Jan 4; 4(115):115ra3.
  10. Gustafson WC, Matthay KK. Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma. Expert Rev Neurother. 2011 Oct; 11(10):1411-23.
  11. Gustafson WC, Weiss WA. Addiction to B-MYB. Oncotarget. 2010 Aug; 1(4):235-6.
  12. Gustafson WC, Weiss WA. Myc proteins as therapeutic targets. Oncogene. 2010 Mar 4; 29(9):1249-59.
  13. Gustafson WC, De Berry BB, Evers BM, Chung DH. Role of gastrointestinal hormones in neuroblastoma. World J Surg. 2005 Mar; 29(3):281-6.
  14. Ray S, Lu Y, Kaufmann SH, Gustafson WC, Karp JE, Boldogh I, Fields AP, Brasier AR. Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis. J Biol Chem. 2004 Aug 20; 279(34):35604-15.
  15. Gustafson WC, Ray S, Jamieson L, Thompson EA, Brasier AR, Fields AP. Bcr-Abl regulates protein kinase Ciota (PKCiota) transcription via an Elk1 site in the PKCiota promoter. J Biol Chem. 2004 Mar 5; 279(10):9400-8.
  16. Fields AP, Murray NR, Gustafson WC. Characterization of the role of protein kinase C isozymes in colon carcinogenesis using transgenic mouse models. Methods Mol Biol. 2003; 233:539-53.
  17. Fields AP, Gustafson WC. Protein kinase C in disease: cancer. Methods Mol Biol. 2003; 233:519-37.
  18. Chen L, Finnerty C, Gustafson WC, Bush CR, Chi P, Guo H, Luxon B, Fields AP, Thompson EA. Genomic analysis of glucocorticoid-regulated promoters in murine T-lymphoma cells. Recent Prog Horm Res. 2003; 58:155-74.
  19. Stuart CA, Wen G, Gustafson WC, Thompson EA. Comparison of GLUT1, GLUT3, and GLUT4 mRNA and the subcellular distribution of their proteins in normal human muscle. Metabolism. 2000 Dec; 49(12):1604-9.
  20. Gustafson WC, Taylor CW, Valdez BC, Henning D, Phippard A, Ren Y, Busch H, Durban E. Nucleolar protein p120 contains an arginine-rich domain that binds to ribosomal RNA. Biochem J. 1998 Apr 15; 331 ( Pt 2):387-93.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.